Should you buy Medtronic stock now?
The technical signal for Medtronic is currently NEUTRAL. Medtronic trades at $86.30 as of 8/6/2026. The overall technical signal is: Hold. The technical analysis shows the following: MACD is positive (bullish trend) at 1.487 with rising momentum (signal: 1.328); RSI is at 58.8 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $98.44 points to 14.1% upside. This is a technical observation based on current data, not investment advice.
What is the price target for Medtronic stock?
The average analyst price target for Medtronic is $98.44. The current price is $86.30, which gives an upside of 14.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $88.60 and $108.28.
Is Medtronic a dividend stock?
Yes, Medtronic is a dividend stock with a dividend yield of 3.28%. The latest dividend was $0.72 per share. The latest ex-dividend date (traded without the dividend) was 6/26/2026. The payout ratio is 51.5%, which is considered moderate. The next dividend payment is scheduled for 7/17/2026.
When does Medtronic pay a dividend in 2026?
Medtronic pays its next dividend on 7/17/2026. The latest dividend was $0.72 per share with an ex-dividend date of 6/26/2026. The dividend yield is 3.28%. The payout ratio of 51.5% points to moderate dividend coverage.
What is the risk of Medtronic stock?
Medtronic is rated as a stock with low risk. the annual standard deviation is 23.6%, which classifies the stock as low risk.
Is Medtronic overvalued?
No, Medtronic is considered undervalued based on the analyst price target (14.1% upside). Medtronic has the following valuation ratios: a P/E ratio of 23.1 (moderately to highly valued), a P/S ratio of 3.0, a P/B ratio of 2.2. The analyst price target suggests that the stock is undervalued by 14.1%.
Is Medtronic overbought?
No, Medtronic is not overbought. RSI is at 58.8 (neutral zone). The technical indicators show: RSI is at 58.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.9% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Medtronic earnings report?
Medtronic reports its next earnings on September 1, 2026. The stock currently trades at $86.30. With a P/E ratio of 23.1, the market will be watching closely whether earnings meet expectations.
Is Medtronic shorted?
Yes, Medtronic is shorted with 1.5% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Medtronic stock?
No, insiders are not buying Medtronic shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 14 sales. On a net basis, 7,906,006 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 7,993,572 $ sold. Active sellers include Walter Matthew R., Thompson Kweli, Martha Geoffrey and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Medtronic a good stock?
Based on our total score, Medtronic is rated as a good stock with a total score of 65 out of 100. The stock scores above average on value, quality and momentum – it is among the top 35% in our database. The score is made up of Value: 62/100, Quality: 81/100, Momentum: 52/100. In addition: analysts see 14.1% upside to the price target; a dividend of 3.28%; technical signal: Hold. Whether Medtronic is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Medtronic stock?
The outlook for Medtronic based on current data: the average analyst price target is $98.44 (+14.1%); the next earnings report is due on 9/1/2026, which can move the price; the P/E ratio is 23.1 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Medtronic stock rising?
Medtronic is rising right now. The technical indicators show: the price is 2.9% above the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Medtronic go?
The average analyst price target for Medtronic is $98.44, which corresponds to a potential gain of 14.1% from the current price of $86.30. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Medtronic fall?
We lack enough history to give a specific floor for Medtronic. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Medtronic do?
Medtronic laver og sælger medicinsk udstyr globalt til hospitaler og læger. De tjener penge på at udvikle avancerede terapier, som hjælper patienter verden over.
Virksomheden er delt op i fire hovedområder: Hjerte/Kredsløb, Neurovidenskab, Kirurgi og Diabetes. De er især kend... The company belongs to the Sundhed sector, more specifically the Medicinprodukter industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Medtronic as an investment.
Did Medtronic raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Medtronic. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Medtronic making money or losing money?
Yes, Medtronic is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 13.2% — which is solid. The operating margin (profit before interest and taxes) is 22.1%. At a P/E ratio of 23.1, you currently pay 23.1 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Medtronic go bankrupt?
The bankruptcy risk of Medtronic is rated as low. Altman Z2 (a model for assessing financial distress) is 3.77 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 90% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Medtronic have a lot of debt?
Medtronic has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 90%. For the sundhed sector, 80-150% counts as a typical level. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Medtronic service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 11.4x, and net debt equals 2.6 years of earnings (EBITDA).
